IQVIA Holdings Inc. (IQV - Free Report) , has been reporting better-than-expected results in the four trailing quarters. The company is known for its global IT infrastructure, analytics-driven clinical development capabilities, and a robust real-world solutions ecosystem.
IQVIA Holdings Inc. reported solid first-quarter 2023 results, wherein earnings and revenues surpassed the Zacks Consensus Estimate. Adjusted earnings per share of $2.45 beat the Zacks Consensus Estimate of $2.41 but declined on a year-over-year basis. Total revenues of $3,652 million outpaced the consensus estimate of $3,608.2 million and increased 2.4% year over year on a reported basis and 4.7% on a constant-currency basis.
Current Situation of IQVIA
IQVIA is serving 85% of the pharmaceuticals operating worldwide. It has a huge collection of healthcare information that comprises pervasive patient records across sales, prescription and promotional data, electronic medical records, medical claims, genomics and social media. The huge database is one of the company’s key assets and is the primary barrier for new entrants.
IQVIA operates in a market that is worth around $300 billion and the company is trying to penetrate deep into these markets by appropriately deploying its information, advanced analytics, transformative technology and significant domain expertise.
Top 5 Dividend Stocks for Your Retirement
Zacks targets 5 well-established companies with solid fundamentals and a history of raising dividends. More importantly, they have the resources and will to likely pay them in the future.
Click now for a Special Report packed with unconventional wisdom and insights you simply won’t get from your neighborhood financial planner.
See our Top 5 now – the report is FREE >>
IQVIA Holdings Inc. (IQV - Free Report) , has been reporting better-than-expected results in the four trailing quarters. The company is known for its global IT infrastructure, analytics-driven clinical development capabilities, and a robust real-world solutions ecosystem.
IQVIA Holdings Inc. reported solid first-quarter 2023 results, wherein earnings and revenues surpassed the Zacks Consensus Estimate. Adjusted earnings per share of $2.45 beat the Zacks Consensus Estimate of $2.41 but declined on a year-over-year basis. Total revenues of $3,652 million outpaced the consensus estimate of $3,608.2 million and increased 2.4% year over year on a reported basis and 4.7% on a constant-currency basis.
Current Situation of IQVIA
IQVIA is serving 85% of the pharmaceuticals operating worldwide. It has a huge collection of healthcare information that comprises pervasive patient records across sales, prescription and promotional data, electronic medical records, medical claims, genomics and social media. The huge database is one of the company’s key assets and is the primary barrier for new entrants.
IQVIA operates in a market that is worth around $300 billion and the company is trying to penetrate deep into these markets by appropriately deploying its information, advanced analytics, transformative technology and significant domain expertise.
Top 5 Dividend Stocks for Your Retirement
Zacks targets 5 well-established companies with solid fundamentals and a history of raising dividends. More importantly, they have the resources and will to likely pay them in the future.
Click now for a Special Report packed with unconventional wisdom and insights you simply won’t get from your neighborhood financial planner.
See our Top 5 now – the report is FREE >>
Get the latest research report on GDOT - FREE
Get the latest research report on MMS - FREE
Get the latest research report on IQV - FREE
Get the latest research report on DOCU - FREE